Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Chunning, Yang"'
Autor:
John S. Schardt, Even Walseng, Kim Le, Chunning Yang, Pooja Shah, Ying Fu, Kausar Alam, Cathryn R. Kelton, Yu Gu, Fengying Huang, Jia Lin, Wenhai Liu, Andrew Dippel, Hanzhi Zhang, Kathy Mulgrew, Stacy Pryts, Vijaykumar Chennupati, Hung-Chang Chen, Jessica Denham, Xiaoru Chen, Pallab Pradhan, Yuling Wu, Colin Hardman, Chihao Zhao, Michael Kierny, Yang Song, Simon J. Dovedi, Saso Cemerski, Yariv Mazor
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
T cell engagers (TCEs) are becoming an integral class of biological therapeutic owing to their highly potent ability to eradicate cancer cells. Nevertheless, the widespread utility of classical CD3-targeted TCEs has been limited by narrow therapeutic
Externí odkaz:
https://doaj.org/article/60b9a30240a24440876eea62946b972e
Autor:
John D. Bagert, Vaheh Oganesyan, Chi-I Chiang, Mike Iannotti, Jia Lin, Chunning Yang, Sterling Payne, Will McMahon, Samuel Edwards, Andrew Dippel, Mark Hutchinson, Fengying Huang, Vineela Aleti, Chendi Niu, Chen Qian, Jessica Denham, Sofia Ferreira, Pallab Pradhan, Mark Penney, Chunlei Wang, Wenhai Liu, Even Walseng, Yariv Mazor
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTBispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of mai
Externí odkaz:
https://doaj.org/article/2704cd42c0734221bbfa24115f8720e9
Autor:
Even Walseng, Bo Wang, Chunning Yang, Pooja Patel, Chihao Zhao, Hanzhi Zhang, Peng Zhao, Yariv Mazor
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many indica
Externí odkaz:
https://doaj.org/article/45a7f57bbc714162955db4f0ce8ebcb9
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Complement-dependent cytotoxicity (CDC) is a potent effector mechanism, engaging both innate and adaptive immunity. Although strategies to improve the CDC activity of antibody therapeutics have primarily focused on enhancing the interaction between t
Externí odkaz:
https://doaj.org/article/5ce3a9d83ee34780b0707e2364352601
Autor:
Walseng, Even, Bo Wang, Chunning Yang, Patel, Pooja, Chihao Zhao, Hanzhi Zhang, Peng Zhao, Mazor, Yariv
Publikováno v:
Frontiers in Immunology; 2023, p01-10, 10p
Autor:
David A. Tice, Robert E. Hollingsworth, Ronald Herbst, Bahija Jallal, Philipp Steiner, Ping Tsui, Partha Chowdhury, Chunning Yang, Leslie Wetzel, Ray Rothstein, Hong Chen, Ravinder Tammali, Krista Kinneer, Kevin Schifferli, Rosa A. Carrasco, Zhan Xiao
HER3/ERBB3 is a kinase-deficient member of the EGFR family receptor tyrosine kinases (RTK) that is broadly expressed and activated in human cancers. HER3 is a compelling cancer target due to its important role in activation of the oncogenic PI3K/AKT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcc96583b01d461e7fb0468a7a88fa35
https://doi.org/10.1158/1535-7163.c.6538702.v1
https://doi.org/10.1158/1535-7163.c.6538702.v1
Autor:
David A. Tice, Robert E. Hollingsworth, Ronald Herbst, Bahija Jallal, Philipp Steiner, Ping Tsui, Partha Chowdhury, Chunning Yang, Leslie Wetzel, Ray Rothstein, Hong Chen, Ravinder Tammali, Krista Kinneer, Kevin Schifferli, Rosa A. Carrasco, Zhan Xiao
Figure 1: KTN3379 specifically binds to HER3; Figure 2: KTN3379 suppresses cell-growth in HRG-HER3 autocrine cells and HRGinduced VEGF secretion; Figure 3: KTN3379 arrests HER2+ breast cancer cells in G0/G1-phase; Figure 4: KTN3379 is inactive in HER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39380c21c500de7b31d46a26363070fb
https://doi.org/10.1158/1535-7163.22507480.v1
https://doi.org/10.1158/1535-7163.22507480.v1
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
Supplementary Materials and Methods, and Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238b4ab5c831dd6063dffdf564c8ad3c
https://doi.org/10.1158/2159-8290.22540037
https://doi.org/10.1158/2159-8290.22540037
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca7eaed273b219faf1bb63ec9cf8694
https://doi.org/10.1158/2159-8290.c.6549263
https://doi.org/10.1158/2159-8290.c.6549263
Autor:
David A. Tice, Robert E. Hollingsworth, Ronald Herbst, Bahija Jallal, Philipp Steiner, Ping Tsui, Partha Chowdhury, Chunning Yang, Leslie Wetzel, Ray Rothstein, Hong Chen, Ravinder Tammali, Krista Kinneer, Kevin Schifferli, Rosa A. Carrasco, Zhan Xiao
Methods and figure legends for supplemental data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e19fb28b03753808f69ff05b3db5351
https://doi.org/10.1158/1535-7163.22507483
https://doi.org/10.1158/1535-7163.22507483